• Go to navigation
  • Go to content
Seloken International

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca Cardiovascular

Main navigation

  • Home
  • The Product
  • Background
  • Ongoing Research
  • Slide Kits
  • Events
  • News
  • Webcasts
  • Press Releases
  • Feedback
  • Toolbox
  • Site map

You are here

  • Home
  • News

  • Pages
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next

Date

    • Aug 19, 2008
    • High-dose rosuvastatin prior to PCI reduces future myocardial injury risk  
    • Aug 18, 2008
    • 'Smoker's paradox' in heart failure not fully explained  
    • Aug 15, 2008
    • Prehospital tirofiban administration improves PCI outcomes  
    • Aug 15, 2008
    • Moderate alcohol intake by post-MI patients may increase HDL cholesterol  
    • Aug 14, 2008
    • Physical exertion intensity modulates impact on AMI risk  
    • Aug 14, 2008
    • Metabolically normal obesity more common than previously thought  
    • Aug 14, 2008
    • Rising anemia rates impact HF survival  
    • Aug 13, 2008
    • Anatomical coronary lesion assessment belies ischemic significance  
    • Aug 13, 2008
    • Valsartan effective against secondary hypertension in preschoolers  
    • Aug 13, 2008
    • Waist-to-height ratio best adiposity measure for calculating CVD risk  
  • Pages
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2008